Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis

Q: What does this research mean for the field?

Continuous terlipressin infusion reduces treatment failure, rebleeding rates, and adverse events in acute oesophageal variceal bleeding compared to bolus administration, while maintaining comparable efficacy for hepatorenal syndrome at lower overall doses. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

Ping‐Han Hsieh; Tsung‐Chieh Yang; Enoch Yi‐No Kang; Yu‐Fu Chen; Pei‐Chang Lee; Kuei‐Chuan Lee; Hui‐Chun Huang; Jiing‐Chyuan Luo; MING‐CHIH HOU

doi:10.1111/liv.70607

March 19, 2026Liver International

Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to compare the effectiveness and safety of continuous versus bolus terlipressin for treating acute oesophageal variceal bleeding and hepatorenal syndrome.
Conducted a meta-analysis of existing studies on terlipressin administration methods.
Compared rates of treatment failure and rebleeding between continuous and bolus terlipressin.
Evaluated overall adverse events and dosage requirements for both administration types.
Continuous terlipressin infusion leads to lower treatment failure and rebleeding rates compared to bolus administration.
In patients with hepatorenal syndrome, continuous infusion shows a comparable response rate to bolus administration.
Lower incidences of total, severe, and cardiovascular adverse events were reported with continuous administration.

Implication

Meta-analysis shows continuous terlipressin reduces treatment failure and adverse events in cirrhosis patients, suggesting it may be preferable.

Abstract

Compared to bolus administration, continuous terlipressin infusion reduces treatment failure and rebleeding rates in patients with AEVB; provides a comparable response rate in patients with HRS; and decreases the incidence of total, severe, and cardiovascular AEs while allowing for lower overall doses.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hsieh et al. (2026) studied this question.

synapsesocial.com/papers/69be35a96e48c4981c674119 https://doi.org/10.1111/liv.70607

View at Publisher

Ask AI

Bookmark

Share

Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Continuous Versus Bolus Terlipressin for Acute Oesophageal Variceal Bleeding and Hepatorenal Syndrome in Cirrhosis: Meta‐Analysis

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Liver International

Keep reading

More related papers

More from Liver International